# Immunocompromised Swiss Cohorts Based Trial Platform

> **NCT04805125** · PHASE3 · COMPLETED · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 610 (actual)

## Conditions studied

- Immunocompromised Patients

## Interventions

- **BIOLOGICAL:** Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)
- **BIOLOGICAL:** Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)

## Key facts

- **NCT ID:** NCT04805125
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-19
- **Primary completion:** 2023-09-23
- **Final completion:** 2023-09-23
- **Target enrollment:** 610 (ACTUAL)
- **Last updated:** 2024-01-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04805125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04805125, "Immunocompromised Swiss Cohorts Based Trial Platform". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04805125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*